| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|||||||||||||||||||
|
louis_leecs
Elite |
31-Jul-2008 22:46
Yells: "half cash" |
||||||||||||||||||
|
x 0
x 0 Alert Admin |
foture predict that 1st half year is 'jia',mean wood no good for stock market,,,,,tomorow is ist day of second half year is 'zi',,,,mouse mean water,,,so stock going to strong rebound all the way to year end ,,,,,so biosenser q steady at 50cts for second day,,,,,,and invisible investor keeping buy when shortist short sell,,,,im waiting tis bb can come out to punish them,,,,,,,the day akan datang,,,,,,,,,hold tight,,,,,,CHIONG AH,,,,,,first to see 60cts first | ||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
bengster68
Master |
31-Jul-2008 10:49
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
Whale Week: John Paulson Fund manager John Paulson made billions betting against subprime-backed securities. Should you trade in his wake? Background Few animals are as notorious as killer whale John Paulson. He learned to swim in the rough seas near Queens, New York. Now he's a blood-thirsty predator who is unafraid to swim against the currents of Wall Street. Just last year he bet against the U.S. housing market. In fact, Paulson scored the largest one-year kill in Wall Street history at $3.7 billion as the rest of the school was harpooned by worthless housing-backed assets. Now that you have a little background, should you trade in his wake? Trades I want to see more from him before I make that decision, counters Jeff Macke. As far as I can tell he got one trade right, it just happened to be a big one! |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
|
|||||||||||||||||||
|
XiaoMaGe888
Senior |
31-Jul-2008 09:18
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
Hello!!!Louis,Are U ok. No fever??
|
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
louis_leecs
Elite |
30-Jul-2008 23:37
Yells: "half cash" |
||||||||||||||||||
|
x 0
x 0 Alert Admin |
termasek buy more share at merryl lynl,,,,,,today oei hong leong start buy in to take over japan land,,,,,tis tykhood will lead the e2 cap boss,,,,,popiah king,,,,,remiserking,,,,local fund mngr start pump billion dollar to buy cheap cheap lelong stock,,,,,,,im waiting they come in,,,,,,,today oei hong leong take action,,,,tomorw newspaper will hrad line after sell all his holding now buy low raqction coming,,,,,,,,,,,,,,,so t biosensor will follow tis boat ,,,,,,,,,,,60cts,,,,,80cts,,,,,,,,even 1.50cts akan datang,,,,,,,,is a signal buy | ||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
investor
Senior |
30-Jul-2008 23:22
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
The technical picture actually looks better, after the recent base building, from the low of 0.46 on the 10th Jul 08. The recent vol has stabilised, and UNLESS there is some bad news on the horizon, I don't see Biosensors breaking 0.46. As the price move sideways, the 20 day moving ave is coming down to meet the price as well as the 10 day mva. Typically, after a consolidation period like this, and IF the stock moves and cut above the 20 days, and stay on top of it thereafter, we may see the begining of a upward move to 0.56 or so. A break above 0.52, with decent volume (maybe 10m or so ?) will lend credence to this viewpoint. As usual, not a call to buy/sell. Contra plays are not advised. |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
|
|||||||||||||||||||
|
louis_leecs
Elite |
30-Jul-2008 22:01
Yells: "half cash" |
||||||||||||||||||
|
x 0
x 0 Alert Admin |
tis invisible investor today take aCTION again,,,,,,,,,50cts for today,,,,,now oil price down again and DOW JONES GOING TO TEST 12000 POINT COMING,,,,,,,,,,BUY TIS BABY U WONT DIE,,,,,,,,,,,WAITING FOR BB TO TAKE ACTION,,,,,,,,,,,,,,,,,,,,so tomoro0w can see hight again,,,,,535 to 675cts possible when tis baby wake up,,,,,,,,,,,,,,,,,in history tis baby always up up up all the way,,,,,,, | ||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
XiaoMaGe888
Senior |
30-Jul-2008 19:31
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
$0.80 very cheap BUY!!!! $.0695 very very cheap ,comfirm make money BUY!! BUY!!! $0.50 very very very cheap BUY!!!BUY!!!BUY!!! How to die also don't know. |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
louis_leecs
Elite |
30-Jul-2008 08:48
Yells: "half cash" |
||||||||||||||||||
|
x 0
x 0 Alert Admin |
hope tis invisible investor can push tis baby out of 50cts,,,,,,,today is a good chance for them to push push all the way,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cheers,,,, | ||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
|
|||||||||||||||||||
|
louis_leecs
Elite |
29-Jul-2008 22:29
Yells: "half cash" |
||||||||||||||||||
|
x 0
x 0 Alert Admin |
look like invisible investor accumulate at 485cts to 495cts ,,,,,,,,,,,,my radar very very close to tis baby,,,,,,,,,,,,,,,,,,,waitimg time,,,,,,,,,,look like akan dTANG........ |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
novena_33
Veteran |
29-Jul-2008 08:21
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
stochastic, macd, OBV & SAR .... as for the parameter im not aware what he use, that will some influences on the out come....
and what indicator u use Singaporegal?
|
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
ROI25per
Master |
28-Jul-2008 21:57
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
U turn alredi in the Xs for pnf charting; 54/48; cut loss @ 48
|
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
singaporegal
Supreme |
28-Jul-2008 21:28
Yells: "Female TA nut" |
||||||||||||||||||
|
x 0
x 0 Alert Admin |
I don't see any bullishness in the TA charts. Most indicators are flat or slightly downtrending. What indicators did that guy use?
|
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
|
|||||||||||||||||||
|
novena_33
Veteran |
28-Jul-2008 09:06
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
was reading an article on other forum, the guy noted that this chart is bullish.... as most indicator have make a U turn.... but need vol... PS: no contra player...i'm sure you will get ur self into trouble.... |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
bengster68
Master |
27-Jul-2008 19:38
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
From the AGM: ................... 2. Someone asked about Credit Sussie report a few days ago. CS said there is likelihood Chinese government may block the deal. CS also said positive LEADERS trial expected but lowered the earnings forcast of BIG for FY10 & FY11. Why CS lower the earnings if LEADERS is good? - The CEO said he has not got any knowledge that Chinese government is trying to block the deal. It is in WeiGao's interest to see the deal go thru for their longer term benefits. What WeiGao see in BIG is DES technology and potential to go global. What BIG see in JWMS is immediate extensive China distribution network to launch their future products in China quickly. CEO said distribution channel in China can be build up but it takes time and he would prefer to buy over JWMS but it is not a do or die thing for BIG. He has contingency plans already in place on how to penetrate into China even without 100% JWMS ownership. - LEADERS trial is as what Mr Investor has described (see his post that i posted couple of days earlier). Its a real world kind of RCT and not narrowing the patient group into playing "soccer on basketball court". Also, LEADERS is challenging the best DES around. Other DES rivals love to challenge Taxus because they know the can beat or be on par against Taxus. Nobody dare to do a challenge with Cypher (Sirolimus) and you got to really have a lot of substance to challenge with Cypher. Its like challenging Manchester United. If you win, you are considered the best of the best. If LEADERS is good, sales will definitely increase which will bring in the profits so CS report about reduction of earnings in FY10 & 11 is wrong and without any basis. 3. Someone asked about BIG's future royalty as it is totally not mentioned in any analysts' forecasted earnings. Royalties as a multiple stream of income and major profit generator has not caght the attention of most investors. - CFO said royalties will begin once licensees products get their regulatory approvals. Among Xtent, Devax and Terumo, he expects royalties from Terumo to be very substantial, esp in Japan market. He said Nobori is still in the progress of obtaining Japan regulatory approvals. However, he would rather not give forecast to analysts on expected royalties 2 or 3 years down the road. (I think BIG is bounded by licensing agreement confidentially clause not to disclose anything without prior consent from the licensee). 4. Someone said JNJ bought Conor at US$1.4B for a stent that cannot work and full of patent ligations. Abbott bought Xience R&D program for US$4.1B whcih is using BIG's older Everolimus IPs. BIG is probably the best stent developer in the world (subject to confirmation of LEADERS results). BIG also has CE Mark and China JWMS but why is BIG's market cap now so pitiful at US$0.35B? Thats is less than 10% of what Abbott paid for an above average performance DES program. - LYC said he is the biggest shareholder of this company and he is also in the same plight as all the rest of shareholders. He assures that the most important asset of this company is the technology and he feels we are indeed the best of the best. He said we are very close to making the biggest break in the DES industry and once we make it, we are unstoppable from there on. We are in the medical device business and the clinically best product has a huge advantage to capture market share and become the top selling product. Michael Keline said he believe we should build a solid company and let people come and offer. He has been thru several M&As in his career and to get the best price for M&A is not making fanciful presentations in selling your company to potential buyers but let them want you and come and buy you. The best way to make them come to you is when they are constantly losing market share month after month to you. Then the buyers will know you are really good. The focus now is building this company's sales, capturing more market share and be the best in stent technology. If you are good, people will come to you. BIG is not abandoning USA market but taking a step back. New Port Beach office in USA is closed and massive STEALTH2 RCT for FDA submission is cancelled. (I think BIG is looking to license out Biomatrix USA territory instead). 5. Someone said BIG's share price dropped substantially after CE because many shareholders grew impatient with BIG's gloomy forecast of continue to make losses for H1 of FY09 and only breakeven for H2 of FY09. How is the sales of Biomatrix doing and Excel's current market share in China. Can BIG revise the forecast if Q1 sales are positive as all the analysts just churn out multiple years of forecasted figures based on your near term forecasted figure. - CFO said when he made the forecast earlier, it was at his true believe that the forecast was not gloomy at the point when he made the projections. A forecast of revenue increase of 2 times in just 1 year is very rarely seen in the corporate world and thats about the amount of growth he forecasted for BIG's internal sales (excluding JWMS). He said he will relook into it and call for another analysts forecast when Q1 results are out. ***BIG is already positive cash flow with Terumo's US$40m cash paid in Apr 2008. BIG is already profitable but they chose to recognise this cash profit over a period of 5 years. For other listed companies, a lot of them do asset revaluation and put them as recognised profit item (but cash was never received). BIG is the only stupid company that received all the cash profit but want to delay recognising them. CFO did not disclose Q1 profitability at AGM. But if BIG's CEO is calling for analysts briefing on Q1 results, i think something positive should come out. We have to read between the lines sometimes to catch hints on what is about to happen. If BIG keep stressing "Best of the Best", i think initial LEADERS trial data received most likely should be very positive. |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
pasttime
Member |
27-Jul-2008 16:48
Yells: "." |
||||||||||||||||||
|
x 1
x 0 Alert Admin |
benbgster68 san, greetings. did you asked when they will be profitable and +ve cash flow ? thanks |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
AK_Francis
Supreme |
26-Jul-2008 17:10
Yells: "Happy go lucky, cheers." |
||||||||||||||||||
|
x 0
x 0 Alert Admin |
68 tks for the efforts, didn't attend the AGM. Nonetheless, confidence on this burger. | ||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
bengster68
Master |
26-Jul-2008 15:01
|
||||||||||||||||||
|
x 1
x 0 Alert Admin |
I spoke to a DES grandmaster at BIG's AGM and asked him a few questions. 1. Why is Biomatrix DES still using stainless steel metal strut as compared to most other DESs which are already using Cobalt Chronium metal strut? - We are aware of some advantages of Cobalt Chronium but we believe Stainless Steel strut has a very huge advantage over Cobalt Chronium and that is the stent diameter recoil factor. Cobalt Chromium DES's recoil is about 9% and that is very huge. You need to expand the balloon catheter even bigger to accommodate the stent recoil after the balloon catheter is deflated. When you do that, you are creating more injury on the vessel wall as the stent surface is pressing / cutting on to the vessel wall even harder as compared to using stainless steel, thereby causing more potential injury to the vessel wall. If you under-inflated the stent (due to recoil), the stent is not going to work effectively as well. 2. Tell me more about your ablumenal coating technology. - BIG has a patent on ablumenal coating of immunosuppressive drug on the stent surface are that is contacting the vessel wall. Any immunosuppressive drug on the non-ablumenal surface of the stent is actually harming the endothelisation process (good cell regrowth over the non-ablumenal surface which reduces blood clot cases). BMS has very excellent endothelisation process on its non-ablumenal surface and the Biomatix is essentially a BMS on the non-ablumenal surface. BIG uses a precision coating machine which can coat a very precise mixture composition of PLA biodegradable polymer and BiolimusA9 drug and at very precise coating thickness of 11um on Biomatrix's ablumenal surface. Without this precise coating machine, this is not possible to achieve. All other DESs uses spray coating technology. The problem about spray coating is it difficult to achieve unifomity of drug coating (esp at the edges and corners). Also, spraying may lead to some particles of immunosuppressive drug being sprayed unintentionally onto the non-ablumenal surface at the same time. Any presence of immunosuppressive drug on the non-ablumenal surface will affect endothelisation progress. http://www.biomatrix.com/product.how.php (see video on the precision coating process) 3. Whats your opinion of reservoir holes strut technology? - I think the reservoir holes theory is flawed. If all the immunosuppressive drugs are lumped and stored in the reservoir holes in concentration, migration of the drug will be more difficult and not efficient. Some area of vessel wall will have more potent drug effect while some area may not have enough drug effect. Since the whole ablumenal stent surface is in "full contact" with the vessel wall and causing "injury" to the vessel wall, it is best for the immunosuppressive drugs to be coated evenly on the entire ablumenal stent surface as each and every mm of the entire ablumenal stent surface is causing stress and "injury" to the vessel wall. The benefits having reservoir holes doesn't justify to make a DES to perform like part DES (reservoir holes in contact with vessel wall) and part BMS (bare metal stent strut surface in contact with vessel wall). Surface area of stents with reservoir holes has to be made broader to make the metal strut more sturdy due to the hundreds of reservoir holes that is weakening the strut strength. This is can cause another problem potentially because the broader the stent surface, the harder it is to achieve good endothelisation process at the non-ablumenal surface. |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
investor
Senior |
26-Jul-2008 13:16
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
Article below shows that the medical community is more and more concern about INCOMPLETE endothelialization as a factor in Late Stent Thrombosis, as well as strut coverage. Xience seems to fare better than Cyper, Taxus and Endeavor, in this study, although the Bio-matrix was not included in the study.
Key Points:
By Kim Dalton In a rabbit model, differences in arterial healing following drug-eluting stent (DES) implantation suggest that the risk of late stent thrombosis may be somewhat lower with the new Xience and Endeavor stents compared to first-generation DES. Differences in the degree of strut neointimal coverage and expression of several biomarkers of incomplete endothelialization favor the newer DES designs, according to a study published in the To assess the effect of various polymer-based DES on endothelialization, researchers led by After stent retrieval at 14 or 28 days, the stented arteries were bisected, with half examined via scanning electron microscopy and half immunostained. Other stented arteries were harvested after the same periods for culturing. (Although 28 days in rabbits is often considered the equivalent of 1 year in humans, the investigators suggest that the shorter 14-day duration may reveal more about the course of vascular healing with DES.) Coverage Gap Differences in total surface area of uncovered struts for the various DES vs. bare-metal stents were most pronounced at 14 days. At that point, the uncovered strut area was smallest for Xience, while Cypher, Taxus, and Endeavor each showed at least a 5-fold greater uncovered area compared to bare-metal controls (table 1). At 28 days, the total uncovered area had decreased ~50% in all DES, although the difference persisted in Taxus. Table 1. Total Area of Uncovered Struts (mm2)
aP < 0.0001 vs. bare-metal controls. bP < 0.05 vs. bare-metal controls. Longitudinal coverage of DES was poorest in the middle regions, whereas the ends were generally well endothelialized—except for Cypher. Biomarkers Signal Delayed Endothelialization In addition, levels of biomarkers indicating the stage of endothelial recovery varied among the different DES along lines similar to those for strut coverage. Expression of platelet-endothelial cell adhesion molecule-1 (PECAM-1) over struts was generally poor in Cypher and Taxus at both 14 and 28 days, suggesting inhibition of endothelial cell proliferation and migration, endothelial cell injury, and/or increased cell turnover. Likewise, expression of thrombomodulin, which regulates platelets and coagulation, was weak or absent in DES, rendering the endothelium thrombogenic. On the other hand, expression of vascular endothelial growth factor (VEGF) was especially elevated in Cypher, Taxus, and Endeavor, an indication of incomplete endothelialization. While acknowledging that the risk of stent thrombosis is associated with a variety of factors, including procedural, lesion, and patient characteristics, the researchers conclude: “[A]ttention should focus on stent strut coverage rather than late loss alone because the persistent lack of coverage . . . may serve as a nidus for thrombosis. Improved stent designs with thinner struts, more biocompatible polymers, or elimination of polymers with optimized drug elution profiles will likely have a profound impact on endothelial coverage." |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
bengster68
Master |
26-Jul-2008 10:39
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
State Of Stent Business CNBC (Leerink Swann) Survey results showing that the use of drug-coated stents continues to bounce back and that prices aren't going down as much as some had thought they would now that there are four players in the U.S. market. Leerink says seven out of 10 stents that are being put in are coated with a drug and that interventional cardiologists--the docs who implant the tiny wire mesh tubes--expect that rate to tick up slightly higher over the next few months. Many analysts had been predicting a price war this year as MDT and ABT busted up the duopoly owned by BSX and JNJ. But Leerink says its research shows that prices are not collapsing. Boston Scientific is selling the new ABT Xience stent under a different brand name, Promus. It's entitled to do that based on the terms of the Guidant acquisition/divestiture. Anyway, Leerink says Promus is "the highest-priced stent on the market which might suggest recent commentary indicating that BSX will be aggressive with price may be overstated." Some have suggested that because the newest ABT-BSX drug-coated stent looks to be better, safer and easier to thread than the competition that the companies might be able to charge a premium. |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
jasonrxz
Senior |
26-Jul-2008 00:33
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
Hi to all... Due to my busy schedule in my new job.. wasn't able to post that often compared to months back.... i am still active in stocks though.. Had saw this opportunity here that BIG is only .49cts and have saw that the price range (movement) for now is small and it's a very good entry point for longer term ( 3 wks or a month) investors.... Should at least see a sizeable gain by then and according to trend of 6 weeks spike discussed last one and the half month ago.. it's long overdue for a spike.. I know some guys here may think that i am talking crap and should keep my mouth shut but it's really a good good entry point now.... Let's hope the ""national day""effect starts as early as next monday Happy weekends to all bros here.... cheers 
|
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||